{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:50:58Z","timestamp":1789530658523,"version":"build-2803163510"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K17824"],"award-info":[{"award-number":["22K17824"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Recombinant tissue-type plasminogen activators (rtPA) effectively dissolve blood clots and improve symptoms in patients with acute ischemic stroke and myocardial infraction. Although rtPA are used in patients taking antiplatelets or anticoagulants to improve clinical outcomes, combination therapy may increase the risk of hemorrhagic transformation (HT) and intracerebral hemorrhage (ICH). However, few studies have investigated the risk of HT and ICH associated with these combination therapies. This study aimed to investigate the adverse-event and drug-drug interaction signals for HT and ICH under combination therapy with alteplase and various antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database. Adverse-event signals were evaluated using the reporting odds ratio and information components, and drug-drug interaction signals were studied using the \u03a9 shrinkage measure, additive, multiplicative, and Chi-square statistics models. We also investigated predictors of HT and ICH, time-to-onset, and outcomes in patients receiving alteplase. HT and\/or ICH signals were detected in patients receiving alteplase in combination with aspirin, P2Y<jats:sub>12<\/jats:sub> inhibitors, cilostazol, ozagrel sodium, direct oral anticoagulants, warfarin potassium, heparin group, or argatroban. Hypertension and diabetes mellitus were significant risk factors for alteplase-induced HT. Most HT and ICH events occurred within 1 day after alteplase administration, and more than 60% of affected patients were not in recovery. In conclusion, continued monitoring is required in patients receiving alteplase in combination with any of the eight types of antiplatelets or the aforementioned anticoagulants. Additionally, the occurrence of HT or ICH within 1 day post-alteplase administration should be considered in patients with hypertension or diabetes mellitus. The findings from this study may help in understanding the risk of HT and ICH induced by rtPA in patients taking antiplatelet or anticoagulant medications, as well as in promoting the appropriate use of rtPA. Further prospective observational studies and randomized controlled trials are needed to assess these finding.<\/jats:p>","DOI":"10.1371\/journal.pone.0329378","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T17:53:31Z","timestamp":1755539611000},"page":"e0329378","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Analysis of hemorrhagic transformation and intracerebral hemorrhage under combination therapy with alteplase and antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2667-7057","authenticated-orcid":true,"given":"Tsuyoshi","family":"Nakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenao","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroka","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"38","key":"pone.0329378.ref001","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"RA Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"12","key":"pone.0329378.ref002","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the Early Management of Patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"WJ Powers","year":"2019","journal-title":"Stroke"},{"issue":"8","key":"pone.0329378.ref003","doi-asserted-by":"crossref","DOI":"10.1136\/neurintsurg-2018-014569","article-title":"European Stroke Organisation (ESO) - European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke","volume":"15","author":"G Turc","year":"2023","journal-title":"J Neurointerv Surg"},{"key":"pone.0329378.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(87)80422-9","article-title":"Molecular mechanism of action of newer thrombolytic agents","volume":"10","author":"D Collen","year":"1987","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"pone.0329378.ref005","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"W Hacke","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0329378.ref006","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","author":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","year":"1995","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0329378.ref007","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(16)30076-X","article-title":"Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis","volume":"15","author":"WN Whiteley","year":"2016","journal-title":"Lancet Neurol"},{"issue":"12","key":"pone.0329378.ref008","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"55","author":"C Bushnell","year":"2024","journal-title":"Stroke"},{"issue":"7","key":"pone.0329378.ref009","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"DO Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"36","key":"pone.0329378.ref010","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"IC Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"pone.0329378.ref011","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jns.2017.06.004","article-title":"Low risk of ICH after reperfusion therapy in acute stroke patients treated with direct oral anti-coagulant","volume":"379","author":"K Suzuki","year":"2017","journal-title":"J Neurol Sci"},{"issue":"3","key":"pone.0329378.ref012","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5853\/jos.2018.01788","article-title":"Consensus guides on stroke thrombolysis for anticoagulated patients from Japan: application to other populations","volume":"20","author":"K Toyoda","year":"2018","journal-title":"J Stroke"},{"issue":"2","key":"pone.0329378.ref013","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)","volume":"29","author":"M Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"pone.0329378.ref014","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.3390\/jcm10235507","article-title":"Angioedema caused by drugs that prevent the degradation of vasoactive peptides: a pharmacovigilance database study","volume":"10","author":"Y Noguchi","year":"2021","journal-title":"J Clin Med"},{"key":"pone.0329378.ref015","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"K Nomura","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"pone.0329378.ref016","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Y Noguchi","year":"2020","journal-title":"Pharm Res"},{"issue":"1","key":"pone.0329378.ref017","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12872-024-04121-5","article-title":"Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis","volume":"24","author":"F Liu","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"pone.0329378.ref018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/14740338.2023.2245745","article-title":"Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"F-E Shi","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0329378.ref019","unstructured":"Japanese Adverse Drug Event Report database, Pharmaceuticals and Medical Devices Agency, Internet. [Accessed 2024 September 10]. https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0006.html"},{"issue":"7","key":"pone.0329378.ref020","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1248\/bpb.b19-00105","article-title":"Analyses of respiratory depression associated with opioids in cancer patients based on the Japanese Adverse Drug Event Report database","volume":"42","author":"H Sugawara","year":"2019","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"pone.0329378.ref021","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.04.001","article-title":"Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society","volume":"22","author":"K Minematsu","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"pone.0329378.ref022","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2176\/nmc.st.2019-0177","article-title":"Guidelines for intravenous thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: a guideline from the Japan Stroke Society","volume":"59","author":"K Toyoda","year":"2019","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"pone.0329378.ref023","doi-asserted-by":"crossref","first-page":"703258","DOI":"10.3389\/fneur.2021.703258","article-title":"Hemorrhagic transformation after ischemic stroke: mechanisms and management","volume":"12","author":"JM Hong","year":"2021","journal-title":"Front Neurol"},{"key":"pone.0329378.ref024","unstructured":"Medical dictionary for regulatory activities. Japanese version. [Accessed 2024 September 10]. https:\/\/www.jmo.gr.jp\/jmo\/servlet\/mdrLoginTop."},{"issue":"4","key":"pone.0329378.ref025","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/STROKEAHA.108.540781","article-title":"Sex differences in stroke epidemiology: a systematic review","volume":"40","author":"P Appelros","year":"2009","journal-title":"Stroke"},{"issue":"14","key":"pone.0329378.ref026","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1161\/01.CIR.0000012747.53592.6A","article-title":"Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey","volume":"105","author":"D Tanne","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"pone.0329378.ref027","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1161\/STROKEAHA.111.644815","article-title":"Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score","volume":"43","author":"M Mazya","year":"2012","journal-title":"Stroke"},{"issue":"12","key":"pone.0329378.ref028","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1161\/STROKEAHA.107.510768","article-title":"Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)","volume":"39","author":"N Wahlgren","year":"2008","journal-title":"Stroke"},{"issue":"3","key":"pone.0329378.ref029","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/STROKEAHA.114.006573","article-title":"Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial","volume":"46","author":"RI Lindley","year":"2015","journal-title":"Stroke"},{"issue":"1","key":"pone.0329378.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000103110","article-title":"Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors","volume":"24","author":"MG Lansberg","year":"2007","journal-title":"Cerebrovasc Dis"},{"issue":"2","key":"pone.0329378.ref031","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009756","article-title":"Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"95","author":"K Malhotra","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"pone.0329378.ref032","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.STR.32.2.438","article-title":"Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)","volume":"32","author":"V Larrue","year":"2001","journal-title":"Stroke"},{"issue":"3","key":"pone.0329378.ref033","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Y Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"pone.0329378.ref034","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug-drug interaction surveillance","volume":"27","author":"GN Nor\u00e9n","year":"2008","journal-title":"Stat Med"},{"issue":"1","key":"pone.0329378.ref035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cpt.2920","article-title":"Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: a pharmacovigilance study based on the FAERS database","volume":"114","author":"S Xia","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"pone.0329378.ref036","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","article-title":"Detecting signals of drug-drug interactions in a spontaneous reports database","volume":"64","author":"BT Thakrar","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"pone.0329378.ref037","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00228-017-2233-3","article-title":"Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems","volume":"73","author":"M Gosho","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0329378.ref038","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1468-1331.2009.02843.x","article-title":"Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis","volume":"17","author":"L Dorado","year":"2010","journal-title":"Eur J Neurol"},{"issue":"7","key":"pone.0329378.ref039","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamaneurol.2024.1312","article-title":"Contemporary prestroke dual antiplatelet use and symptomatic intracerebral hemorrhage risk after thrombolysis","volume":"81","author":"TJ Peng","year":"2024","journal-title":"JAMA Neurol"},{"issue":"2","key":"pone.0329378.ref040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1161\/STROKEAHA.109.559724","article-title":"Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset","volume":"41","author":"J Diedler","year":"2010","journal-title":"Stroke"},{"issue":"1","key":"pone.0329378.ref041","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaneurol.2015.3106","article-title":"Risks and benefits associated with prestroke antiplatelet therapy among patients with acute ischemic stroke treated with intravenous tissue plasminogen activator","volume":"73","author":"Y Xian","year":"2016","journal-title":"JAMA Neurol"},{"issue":"5","key":"pone.0329378.ref042","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000319029","article-title":"Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?","volume":"30","author":"MM Ibrahim","year":"2010","journal-title":"Cerebrovasc Dis"},{"issue":"3","key":"pone.0329378.ref043","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/STROKEAHA.111.625574","article-title":"The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study","volume":"43","author":"AD Barreto","year":"2012","journal-title":"Stroke"},{"issue":"3","key":"pone.0329378.ref044","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jstrokecerebrovasdis.2011.07.016","article-title":"Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan","volume":"22","author":"S Kono","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"3","key":"pone.0329378.ref045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000334662","article-title":"Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants","volume":"33","author":"M-C Matute","year":"2012","journal-title":"Cerebrovasc Dis"},{"issue":"5","key":"pone.0329378.ref046","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archneurol.2010.25","article-title":"Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke","volume":"67","author":"S Prabhakaran","year":"2010","journal-title":"Arch Neurol"},{"issue":"8","key":"pone.0329378.ref047","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.63.8.1057","article-title":"Argatroban tPA stroke study: study design and results in the first treated cohort","volume":"63","author":"RM Sugg","year":"2006","journal-title":"Arch Neurol"},{"issue":"5","key":"pone.0329378.ref048","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/01.STR.23.5.646","article-title":"Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke","volume":"23","author":"R von Kummer","year":"1992","journal-title":"Stroke"},{"issue":"6","key":"pone.0329378.ref049","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/STROKEAHA.117.016720","article-title":"Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)","volume":"48","author":"AD Barreto","year":"2017","journal-title":"Stroke"},{"issue":"12","key":"pone.0329378.ref050","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.036","article-title":"Safety and feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study)","volume":"27","author":"K Berekashvili","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"2","key":"pone.0329378.ref051","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ana.23924","article-title":"Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin","volume":"74","author":"MV Mazya","year":"2013","journal-title":"Ann Neurol"},{"issue":"5","key":"pone.0329378.ref052","doi-asserted-by":"crossref","first-page":"105678","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105678","article-title":"Safety of intravenous thrombolysis for acute ischemic stroke in patients taking warfarin with subtherapeutic INR","volume":"30","author":"A Mowla","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"19","key":"pone.0329378.ref053","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025809","article-title":"Intravenous thrombolysis with alteplase at 0.6\u2009mg\/kg in patients with ischemic stroke taking direct oral anticoagulants","volume":"11","author":"T Okada","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"pone.0329378.ref054","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000071114","article-title":"Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke","volume":"16","author":"S Schm\u00fclling","year":"2003","journal-title":"Cerebrovasc Dis"},{"issue":"4","key":"pone.0329378.ref055","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/STROKEAHA.110.599183","article-title":"Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator","volume":"42","author":"MDI Vergouwen","year":"2011","journal-title":"Stroke"},{"issue":"24","key":"pone.0329378.ref056","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1001\/jama.2012.6756","article-title":"Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator","volume":"307","author":"Y Xian","year":"2012","journal-title":"JAMA"},{"issue":"12","key":"pone.0329378.ref057","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1161\/01.STR.0000101752.23813.C3","article-title":"Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data","volume":"34","author":"GD Graham","year":"2003","journal-title":"Stroke"},{"issue":"7","key":"pone.0329378.ref058","article-title":"Thrombolysis for acute ischaemic stroke","volume":"2014","author":"JM Wardlaw","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9411","key":"pone.0329378.ref059","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(04)15692-4","article-title":"Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials","volume":"363","author":"W Hacke","year":"2004","journal-title":"Lancet"},{"issue":"9834","key":"pone.0329378.ref060","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/S0140-6736(12)60738-7","article-title":"Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis","volume":"379","author":"JM Wardlaw","year":"2012","journal-title":"Lancet"},{"issue":"9558","key":"pone.0329378.ref061","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study","volume":"369","author":"N Wahlgren","year":"2007","journal-title":"Lancet"},{"issue":"9834","key":"pone.0329378.ref062","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial","volume":"379","author":"IST-3 collaborative group","year":"2012","journal-title":"Lancet"},{"issue":"24","key":"pone.0329378.ref063","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","article-title":"Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke","volume":"374","author":"CS Anderson","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0329378.ref064","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1161\/STROKEAHA.116.013644","article-title":"Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials","volume":"47","author":"KR Lees","year":"2016","journal-title":"Stroke"},{"key":"pone.0329378.ref065","volume-title":"Davies\u2019s textbook of adverse drug reactions","author":"DM Davies","year":"1998","edition":"5"},{"key":"pone.0329378.ref066","doi-asserted-by":"crossref","first-page":"661955","DOI":"10.3389\/fneur.2021.661955","article-title":"Hemorrhagic transformation in ischemic stroke and the role of inflammation","volume":"12","author":"E Spronk","year":"2021","journal-title":"Front Neurol"},{"issue":"1","key":"pone.0329378.ref067","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/01.STR.32.1.12","article-title":"Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage","volume":"32","author":"AM Lopez-Yunez","year":"2001","journal-title":"Stroke"},{"issue":"6","key":"pone.0329378.ref068","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","article-title":"Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration","volume":"24","author":"NR Hartnell","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"10","key":"pone.0329378.ref069","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"A Pariente","year":"2007","journal-title":"Drug Saf"},{"issue":"12","key":"pone.0329378.ref070","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","article-title":"An experimental investigation of masking in the US FDA adverse event reporting system database","volume":"33","author":"H Wang","year":"2010","journal-title":"Drug Saf"},{"issue":"6","key":"pone.0329378.ref071","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Y Noguchi","year":"2021","journal-title":"Brief Bioinform"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T17:53:39Z","timestamp":1755539619000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329378"}},"subtitle":[],"editor":[{"given":"Hong-Jie","family":"Jhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":71,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329378","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}